Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
- PMID: 18703743
- DOI: 10.1126/science.1158545
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Abstract
Previous attempts have shown the potential of T cells in immunotherapy of cancer. Here, we report on the clinical activity of a bispecific antibody construct called blinatumomab, which has the potential to engage all cytotoxic T cells in patients for lysis of cancer cells. Doses as low as 0.005 milligrams per square meter per day in non-Hodgkin's lymphoma patients led to an elimination of _target cells in blood. Partial and complete tumor regressions were first observed at a dose level of 0.015 milligrams, and all seven patients treated at a dose level of 0.06 milligrams experienced a tumor regression. Blinatumomab also led to clearance of tumor cells from bone marrow and liver. T cell-engaging antibodies appear to have therapeutic potential for the treatment of malignant diseases.
Similar articles
-
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.J Clin Oncol. 2016 Apr 1;34(10):1104-11. doi: 10.1200/JCO.2014.59.1586. Epub 2016 Feb 16. J Clin Oncol. 2016. PMID: 26884582 Clinical Trial.
-
Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab.Exp Cell Res. 2011 May 15;317(9):1255-60. doi: 10.1016/j.yexcr.2011.03.010. Epub 2011 Mar 16. Exp Cell Res. 2011. PMID: 21419116 Review.
-
_targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.J Clin Oncol. 2011 Jun 20;29(18):2493-8. doi: 10.1200/JCO.2010.32.7270. Epub 2011 May 16. J Clin Oncol. 2011. PMID: 21576633 Clinical Trial.
-
Blinatumomab: a historical perspective.Pharmacol Ther. 2012 Dec;136(3):334-42. doi: 10.1016/j.pharmthera.2012.07.013. Epub 2012 Aug 24. Pharmacol Ther. 2012. PMID: 22940266 Review.
-
The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).Best Pract Res Clin Haematol. 2012 Jun;25(2):185-90. doi: 10.1016/j.beha.2012.04.005. Epub 2012 May 18. Best Pract Res Clin Haematol. 2012. PMID: 22687454 Review.
Cited by
-
Chemically Programmed Bispecific Antibodies in Diabody Format.J Biol Chem. 2016 Sep 9;291(37):19661-73. doi: 10.1074/jbc.M116.745588. Epub 2016 Jul 21. J Biol Chem. 2016. PMID: 27445334 Free PMC article.
-
Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical model.Front Immunol. 2024 Feb 7;15:1357716. doi: 10.3389/fimmu.2024.1357716. eCollection 2024. Front Immunol. 2024. PMID: 38384461 Free PMC article.
-
Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy.Sci Rep. 2016 Aug 22;6:31621. doi: 10.1038/srep31621. Sci Rep. 2016. PMID: 27546726 Free PMC article.
-
Single domain antibody-based bispecific antibody induces potent specific anti-tumor activity.Cancer Biol Ther. 2016 Dec;17(12):1231-1239. doi: 10.1080/15384047.2016.1235659. Epub 2016 Sep 19. Cancer Biol Ther. 2016. PMID: 27645568 Free PMC article.
-
Ex-vivo CS1-OKT3 dual specific bivalent antibody-armed effector T cells mediate cellular immunity against multiple myeloma.Sci Rep. 2023 Nov 27;13(1):20853. doi: 10.1038/s41598-023-47115-7. Sci Rep. 2023. PMID: 38012196 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
